加拿大 -
英文 -
Health Canada
midodrine tablet
sanis health inc - midodrine hydrochloride - tablet - 5mg - midodrine hydrochloride 5mg
英国 -
英文 -
MHRA (Medicines & Healthcare Products Regulatory Agency)
midodrine 2.5mg tablets
zentiva pharma uk ltd - midodrine hydrochloride - oral tablet - 2.5mg
英国 -
英文 -
MHRA (Medicines & Healthcare Products Regulatory Agency)
midodrine 5mg tablets
zentiva pharma uk ltd - midodrine hydrochloride - oral tablet - 5mg
爱尔兰 -
英文 -
HPRA (Health Products Regulatory Authority)
midon 5 mg tablets
originalis b.v. - midodrine hydrochloride - tablet - midodrine
马来西亚 -
英文 -
NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
miron 5mg tablets
novugen pharma sdn. bhd. - midodrine hydrochloride -
马来西亚 -
英文 -
NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
miron 2.5mg tablets
novugen pharma sdn. bhd. - midodrine hydrochloride -
马来西亚 -
英文 -
NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
miron 10mg tablets
novugen pharma sdn. bhd. - midodrine hydrochloride -
爱尔兰 -
英文 -
HPRA (Health Products Regulatory Authority)
midon tablets 2.5 milligram
nycomed uk limited - midodrine hydrochloride - tablets - 2.5 milligram
爱尔兰 -
英文 -
HPRA (Health Products Regulatory Authority)
midon tablets 5 milligram
nycomed uk limited - midodrine hydrochloride - tablets - 5 milligram
新西兰 -
英文 -
Medsafe (Medicines Safety Authority)
gutron
douglas pharmaceuticals limited - midodrine hydrochloride 2.5mg - tablet - 2.5 mg - active: midodrine hydrochloride 2.5mg excipient: hydrated silica magnesium stearate microcrystalline cellulose purified talc starch - gutron is indicated to attenuate symptoms of chronic orthostatic hypotension due to automatic failure in patients with bradbury-eggleston or shy-drager syndromes and other medical disorders such as diabetes mellitus or parkinson's disease. because midodrine can cause marked elevation of supine blood pressure, it should only be used in patients whose lives are considerably impaired despite standard clinical care including non-pharmacologic treatment, plasma volume expansion and lifestyle alterations. the initiation of gutron therapy should be undertaken under close medical supervision in a controlled clinical setting.